Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?
Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.
Citius Oncology tests LYMPHIR before CAR-T therapy in DLBCL. Does immune modulation improve response durability?
Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.